Induction of systemic TNFα in Natalizumab-treated multiple sclerosis

European Journal of Neurology

Volumn 15, Issue 3, 2008, Pages 309-312

  Khademi, M ^a,b   Stol, D ^a   Olsson, T ^a,b   Wallstrom E ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fatigue; Multiple sclerosis; Natalizumab; TNF

Indexed keywords

ACEBUTOLOL; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 23; INTERLEUKIN 4; MESSENGER RNA; NATALIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; BLOOD CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; HISTORY; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD CELLS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39149138486     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.02037.x     Document Type: Article

References (12)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. The New England Journal of Medicine 2006 354 : 899 910.
2. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Annals of Neurology 2006 59 : 743 747.
3. Scott LM, Priestley GV, Papayannopoulou T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Molecular and Cellular Biology 2003 23 : 9349 9360.
4. Kos D, Kerckhofs E, Nagels G, D'Hooghe MB, Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabilitation and Neural Repair 2007.
5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology 2005 58 : 840 846.
6. Khademi M, Illes Z, Gielen AW, et al. T-Cell Ig- and mucin-domain- containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. Journal of Immunology 2004 172 : 7169 7176.
7. Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nature Genetics 2007 39 : 1108 1113.
8. Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Bruck W. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 2000 29 : 366 375.
9. Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: an example of cytokine-mediated sickness behaviour? Journal of Neurology, Neurosurgery and Psychiatry 2006 77 : 34 39.
10. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007 68 : 1390 1401.
11. Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002 15 : 559 567.
12. Stuve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Archives of Neurology 2006 63 : 1383 1387.